Anavex Life Sciences has reported that the benefits its experimental pill blarcamesine (Anavex 2-73) produced after one year in people with early Alzheimer's disease held up over nearly three years. In the company's Phase 2b/3 trial, patients on the oral medication showed less loss of brain volume - a standard marker of neurodegeneration - alongside improvements in cognition, daily function, and overall disease severity at the one-year mark. A new analysis combining that trial with its long-term extension found those trends persisted, with slower disease progression over three years.
The findings were presented in an oral session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases, held March 17-21 in Copenhagen and online. Christopher U. Missling, PhD, Anavex's president and CEO, said in a company press release that the clinical effects are "biologically coherent" with the MRI-based measures of neuroprotection, arguing that the link between preserved brain structure and functional outcomes supports the company's push toward a disease-modifying treatment.
Why that framing matters: the currently approved disease-modifying Alzheimer's drugs are given by infusion, which means clinic visits, monitoring, and considerable time commitment for patients and families. The title of the conference presentation itself emphasized convenience and long-term time saved, signaling that Anavex sees a daily pill as the practical selling point as much as the biology.
The usual caution applies to data of this kind. This is an analysis conducted and announced by the drug's developer, delivered as a conference presentation rather than a peer-reviewed publication, and blarcamesine remains investigational. Open-label extension studies, in which participants continue treatment beyond the controlled phase, are also harder to interpret than randomized comparisons. Independent scrutiny of the full dataset will determine how much weight the three-year signal carries.